The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.
February 2nd 2025
Once-weekly tirzepatide may be an alternative to daily hormone shots in patients with congenital generalized lipodystrophy.
HCPLive Endocrinology's flagship diabetes podcast, hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP
Thyroid Combination Therapy Preferred Over Levothyroxine for Some Hypothyroidism Patients
March 21st 2021A randomized, 3-arm study is giving further insight into the effects of levothyroxine monotherapy compared against a thyroid combination therapy and desiccated thyroid extract for management of hypothyroidism, particularly in patients with Thr92AlaD2 polymorphism.
Many Endocrine Providers, Patients Open to Continuing Telehealth Practices
March 21st 2021An analysis of patients and providers from endocrine clinics suggests many patients and providers were open to continuing with telehealth practices after the pandemic and many saw little to no limitations with the new practices.
Children with Adrenal Insufficiency at 10 Times Greater Mortality Risk from COVID-19
March 20th 2021An analysis by investigators from the University of Arkansas suggests children with adrenal insufficiency were 10 times more likely to die from COVID-19 than their counterparts without adrenal insufficiency and COVID-19.
Comparing ADA vs. ACOG Approaches for Gestational Diabetes Screenings
March 16th 2021A trial of more than 20k women from investigators at Kaiser Permanente found there were no significant differences in outcomes among pregnant women undergoing gestational diabetes screenings using the ADA's 1-step approach versus the ACOG's 2-step approach.
Who is Responsible for Prescribing Weight Loss Medications to Obese Patients with Thomas Wadden, PhD
March 5th 2021After providing insight into the results of the STEP 1 and STEP 3 trials, Dr. Wadden discusses who he believes the responsibility for prescribing these medications will fall unto if semaglutide receives approval as a weight loss agent.
STEP 1 and STEP 3 Results with Thomas Wadden, PhD
March 2nd 2021Published in late February, results of the STEP 1 and STEP 3 trial give clinicians insight into the effects of 2.4 mg subcutaneous semaglutide as an intervention for weight loss in overweight or obese patients ahead of a potential approval in June 2021.
Abnormal Sodium Levels Predict Risk of Mortality, Need for Ventilatory Support in COVID-19 Patients
February 26th 2021An analysis of nearly 500 patients hospitalized with COVID-19 from London suggests dysnatremia could help signal which patients were at an increased risk of complications, including death and need for respiratory support.